BrightSpring Health Services, Inc. Common Stock (BTSG) Q4 FY25 Earnings Call

2026 EBITDA guidance implies 23.1%-27.9% growth despite approximately $600 million of pharmacy revenue headwinds. [60][98]

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-28
Length58 minutes
EPS$0.33
EPS consensus$0.34
Revenue$3.6B
Revenue consensus$3.4B

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26 · Q2 FY25

All BTSG earnings · Back to BTSG overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.